Robust real-world data on the effectiveness of biologic therapies in children with severe asthma remain limited, particularly ...

Nonclinical factors are more likely to drive discontinuation of biologic therapy for patients with severe asthma.

To inform clinicians on the best biologic agent for different populations of adults with severe asthma, 12 experts collaborated on a new clinical practice guideline published in CHEST, according to a ...

Real-world data from 2016 to 2025 highlight the changing landscape of biologic use and the growing preference for tezepelumab in asthma.

Asthma biologic use was not associated with an increase in respiratory infection risk, according to results from the 2026 ...

Please provide your email address to receive an email when new articles are posted on . Researchers assessed patients receiving omalizumab, dupilumab, mepolizumab, benralizumab, reslizumab or ...

Earlier initiation of biologics in severe asthma could prevent thousands of deaths and save billions in healthcare costs by reducing exacerbations and healthcare resource utilization. Real-world data ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...

A new option for hard-to-control asthma: The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma. Designed to reduce flare-ups: The injectable ...

PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) said the U.S. Food and Drug Administration has approved Exdensur, a twice-yearly biologic treatment for patients with severe asthma characterized by an ...

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet in Sweden shows that some immune cells with high inflammatory potential are ...

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use has recommended the granting of a marketing authorization for Exdensur (depemokimab, GlaxoSmithKline) for severe ...